Durable Response to Sequential ROS1-TKIs in Metastatic Squamous NSCLC With EZR-ROS1 Fusion: A Case Report

Anne Mette A. Konradsen; Eva S. Petersson; Morten Grauslund; Morten H. Suppli; Siv S.M. Berger; Pia H. Klausen; Jens B. Sørensen; Eric Santoni-Rugiu; Edyta M. Urbanska

doi:10.1016/j.cllc.2026.02.008

Durable Response to Sequential ROS1-TKIs in Metastatic Squamous NSCLC With EZR-ROS1 Fusion: A Case Report

Anne Mette A. Konradsen^*, Eva S. Petersson, Morten Grauslund, Morten H. Suppli, Siv S.M. Berger, Pia H. Klausen, Jens B. Sørensen, Eric Santoni-Rugiu, Edyta M. Urbanska

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

Clinical Practice Points • ROS1 fusion may occur in pulmonary squamous cell carcinoma (LUSC). • This is the first case of sustained clinical and radiological response to sequential ROS-TKIs therapy in advanced LUSC. • Molecular testing may be considered in patients with advanced LUSC when further treatment options are limited.

Original language	English
Journal	Clinical Lung Cancer
Volume	27
Issue number	3
Pages (from-to)	22-27
Number of pages	6
ISSN	1525-7304
DOIs	https://doi.org/10.1016/j.cllc.2026.02.008
Publication status	Published - 2026

Bibliographical note

Publisher Copyright:
© 2026 Elsevier Inc.

Keywords

Crizotinib
Entrectinib
NGS
Pulmonary Squamous Cell Carcinoma

Access to Document

10.1016/j.cllc.2026.02.008

Library access?

Check availability at the Royal Danish Library

Cite this

@article{4bffbb42c0814815823866852185bfd9,

title = "Durable Response to Sequential ROS1-TKIs in Metastatic Squamous NSCLC With EZR-ROS1 Fusion: A Case Report",

abstract = "Clinical Practice Points • ROS1 fusion may occur in pulmonary squamous cell carcinoma (LUSC). • This is the first case of sustained clinical and radiological response to sequential ROS-TKIs therapy in advanced LUSC. • Molecular testing may be considered in patients with advanced LUSC when further treatment options are limited.",

keywords = "Crizotinib, Entrectinib, NGS, Pulmonary Squamous Cell Carcinoma",

author = "Konradsen, {Anne Mette A.} and Petersson, {Eva S.} and Morten Grauslund and Suppli, {Morten H.} and Berger, {Siv S.M.} and Klausen, {Pia H.} and S{\o}rensen, {Jens B.} and Eric Santoni-Rugiu and Urbanska, {Edyta M.}",

note = "Publisher Copyright: {\textcopyright} 2026 Elsevier Inc.",

year = "2026",

doi = "10.1016/j.cllc.2026.02.008",

language = "English",

volume = "27",

pages = "22--27",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Durable Response to Sequential ROS1-TKIs in Metastatic Squamous NSCLC With EZR-ROS1 Fusion

T2 - A Case Report

AU - Konradsen, Anne Mette A.

AU - Petersson, Eva S.

AU - Grauslund, Morten

AU - Suppli, Morten H.

AU - Berger, Siv S.M.

AU - Klausen, Pia H.

AU - Sørensen, Jens B.

AU - Santoni-Rugiu, Eric

AU - Urbanska, Edyta M.

PY - 2026

Y1 - 2026

N2 - Clinical Practice Points • ROS1 fusion may occur in pulmonary squamous cell carcinoma (LUSC). • This is the first case of sustained clinical and radiological response to sequential ROS-TKIs therapy in advanced LUSC. • Molecular testing may be considered in patients with advanced LUSC when further treatment options are limited.

AB - Clinical Practice Points • ROS1 fusion may occur in pulmonary squamous cell carcinoma (LUSC). • This is the first case of sustained clinical and radiological response to sequential ROS-TKIs therapy in advanced LUSC. • Molecular testing may be considered in patients with advanced LUSC when further treatment options are limited.

KW - Crizotinib

KW - Entrectinib

KW - NGS

KW - Pulmonary Squamous Cell Carcinoma

U2 - 10.1016/j.cllc.2026.02.008

DO - 10.1016/j.cllc.2026.02.008

M3 - Journal article

C2 - 41903499

AN - SCOPUS:105033612879

SN - 1525-7304

VL - 27

SP - 22

EP - 27

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 3

ER -